Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002742 · ClinicalTrials.gov registry record · Phase 3
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
A Phase 3 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 3
- Development phase
- 236
- Enrollment target
NCT01002742 is a Phase 3 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 236 participants.
The verdict
NCT01002742, a Phase 3 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 236 participants
- Enrollment target
Study Summary
The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD free survival at Day 56 post randomization.
Interventions
- DRUG Placebo
- DRUG Mycophenolate Mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002742
The ClinicalTrials.gov registry entry for NCT01002742 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01002742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002742 about?
NCT01002742 is a clinical study titled "Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)". The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD free survival at Day 56 post ra...
What is the current status of trial NCT01002742?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 236 participants. The study started on 2010-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01002742?
The interventions under investigation include: Placebo (DRUG), Mycophenolate Mofetil (DRUG).
Who is sponsoring clinical trial NCT01002742?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.